Objective: To determine the effect of nonesterified, nonhydrogenated plant sterols solubilized in a partly vegetable oil-filled low-fat milk on serum low-density lipoprotein cholesterol (LDL) in mildly hypercholesterolemic patients. Design: Double-blind, randomized, placebo-controlled three-arm crossover study. Setting: Outpatient clinical trial. Subjects: A total of 138 patients were screened, providing 81 patients for randomization; 71 patients completed the study. Interventions: The study product was a 500 ml milk blend with or without nonesterified, nonhydrogenated sterols. The daily consumption of sterols in the three groups was 0 g/day, control group (C); 1.2 g/day, (Lo); or 1.6 g/day, (Hi), respectively. The patients were randomly assigned to one of three different treatment sequences. Each intervention period was 4 weeks. The total study duration was 12 weeks. Results: The milk product was well tolerated. The placebo-adjusted mean reduction in LDL was 7.13712.31 and 9.59712.44% (mean7s.d.) for Lo and Hi groups, respectively (Po0.0001); there was no statistically significant difference in LDL lowering for the Lo and Hi groups. There were no significant changes in serum vitamin E or carotenoid concentrations after standardization with LDL cholesterol during the study period.
Introduction
One of the most important risk factors for cardiovascular disease is hypercholesterolemia. The cholesterol level is controlled by cholesterol absorption from the diet and by endogenous cholesterol synthesis. The absorption of cholesterol from the intestinal milieu occurs through a series of steps, involving emulsification, hydrolysis, micellar transport, mucosal absorption, resynthesis of parent molecules in enterocytes, and assembly with apolipoproteins to form chylomicrons, which are secreted from intestinal cells (Lu et al, 2001) . Some or all of these steps can be interfered with by dietary components and drugs (Ros, 2000) . Several studies have confirmed the effect of plant sterols or stanols on inhibiting cholesterol absorption (Pelletier et al, 1995; Christiansen et al, 2001) and examined the mechanism of action (Berge et al, 2002; Cui et al, 2003; Igel et al, 2003) . Accordingly, it has now been recognised by the United States Federal Drug Administration (US FDA) and the American Heart Association that adding sterols or stanols to the diet may lower the blood cholesterol level and thereby reduce the risk of cardiovascular disease (FDA, 2000; Lichtenstein & Deckelbaum, 2001; Moreau et al, 2002) .
A limitation of most of the previous studies has been that because of the solubility properties of plant sterols and stanols, they have been added (typically as esters) to oily food vehicles such as margarines or dressings (Miettinen et al, 1995; Hallikainen et al, 2000) . There have been far fewer studies examining the effects of plant sterols or stanols in low-fat matrices (Beer et al, 2001; Volpe et al, 2001; Lea, 2002; Mensink et al, 2002; Pouteau et al, 2003) , and no other studies examining the effects of nonesterified, nonhydrogenated plant sterols in a partly vegetable oil filled low-fat milk. Partly vegetable oil-filled milks provide a potentially healthier fatty acid profile for reducing cholesterol than intact milk fat. However, full fat-containing milks have fat globule membrane components (phospholipids, fatty acids, glycolipids, etc) that could enhance the absorption of cholesterol, making it more difficult for the plant sterols to inhibit cholesterol absorption and lower low-density lipoprotein cholesterol (LDL). Indeed, it was previously found that the basal cholesterol absorption rate was 70.1% in subjects consuming partly vegetable oil-filled low-fat milks without plant sterols (Pouteau et al, 2003) compared to a value of only 55.7% in subjects consuming a mayonnaisetype product without plant sterols (Gremaud et al, 2001 ). The quantity of fat being provided was different in these two studies, which could also be a variable affecting basal cholesterol absorption.
Free nonesterified sterols are difficult to add to various food matrices, because they readily form insoluble crystals. Large-sized plant sterol crystals (unless present in large quantities in the diet) will not efficaciously reduce the absorption of cholesterol in vivo (Miettinen & Vanhanen, 1994; Denke, 1995) , whereas noncrystalline preparations (Ostlund, 2000) and preparations containing microsized crystals (Christiansen et al, 2001 ) are efficient and efficacious. Hence, proprietary strategies to solubilize nonesterified plant sterols are needed.
In the present study, we determined the effect of nonesterified, nonhydrogenated sterols, properly solubilized in a partly vegetable oil-filled low-fat milk, on serum LDL in mildly hypercholesterolemic patients, who consumed their habitual diets with some restrictions on high-fat foods.
Material and methods

Design
The study was a double-blind, randomized, three-arm crossover study performed at The Centre of Clinical and Basic Research (CCBR; Copenhagen, Denmark). All aspects of the study were closely monitored by Nestec Ltd and found to be in accordance with Good Clinical Practice (ICH-GCP). The subjects received all three treatments in different order, as a three-period crossover design with no washout period.
Each subject was randomly assigned to one of the following three intervention sequences:
Sequence 1: Placebo milk (control)-sterols low-sterols high, (C)-(Lo)-(Hi);
Sequence 2: Sterols low-sterols high-control milk, (Lo)-(Hi)-(C);
Sequence 3: sterols high-control milk-sterols low, (Hi)-(C)-(Lo).
Each treatment period was 4 weeks, and accordingly the total study duration was 12 weeks.
Study product
Test products were manufactured under factory-controlled conditions at Nestlé Product Technology Centre Konolfingen (Konolfingen, Switzerland). The study product was 500 ml of a 1.2% fat (analyzable fat, excluding sterol contribution to fat), ultra high temperature (UHT) shelf stable milk product with or without unesterified, unhydrogenated sterols, predominantly from soybeans (Pouteau et al, 2003) . The caloric and fat consumption of the patients was not determined. Assuming a 2000 kcal diet with 40en% fat, the milk products would contribute approximately 7en% of daily total fat intake. A portion of the milk fat was replaced by a vegetable oil blend providing 0.79 wt% fat (g fat/100 g product) consisting of 0.46 wt% rapeseed oil (Aarhus Oliefabrik, Aarhus C, Denmark) and 0.33 wt% corn oil (unless stated otherwise, ingredients were from Nestlé stocks). Butter oil was added at 0.10-0.42 wt% for taste purposes, and to balance the contribution of fat contributed from the proprietary emulsifier utilized. Milks containing the above vegetable oil mixture are commercially known as OMEGA PLUS milks (Nestlé, Switzerland).
The fatty acid composition of the products (based on fatty acid analysis of each individual component) was as follows: o8:0 (3.8, 1.8, 1.2 wt% of total fatty acids, for C, Lo, and Hi products, respectively); 8:0 þ 10:0 þ 12:0 (2.7, 1.4, 0.9); 14:0 (3.6, 2.0, 1.4); 16:0 (14.2, 18.4, 19.9); 16:1n7 (1.0, 0.6, 0.4); 18:0 (5.1, 11.3, 13.5); 18:1n9/7 (38.2, 34.7, 33.6); 18:2n6 (22.4, 22.5, 22.5); 18:3n3 (3.6, 3.5, 3.5) ; 20:0 þ 20:1n9 þ 22:0 (1.2, 1.2, 1.2); and other fatty acids (4.2, 2.6, 2.0). According to the equations of Yu et al (1995) , relative to C, the fatty acids in the Lo and Hi products could lower LDL only 0.0069 and 0.009 mmol/l, respectively. Thus, the fatty acid components of the three milk products would not be responsible for any observed reductions in cholesterol between the three products. From the analyzed fatty acid composition of each component, the saturated fat intake/250 ml serving was 0.96, 1.10, and 1.15 g for the C, Lo, and Hi products, respectively. There were also 9.1% skim milk powder and 0.028% total vitamins (A, D 3 , and E) in the formulations.
The formulations were engineered to provide 0.0 g/day (C), 1.2 g/day (Lo), and 1.6 g/day (Hi), respectively, of pure free plant sterols, provided as two milk servings of 250 ml per day, taken immediately after breakfast and lunch. The sterols were 92.5% pure. The amounts of sterols in the milks were also quantified and verified following extraction and gas chromatography using Nestlé internal quality control procedures (Laboratory Instruction 00.531, Nestlé Laboratorio Regionale, Milan, Italy). There were 0.00970.0001, 0.23370.0013, and 0.31970.001% free sterols in C, Lo, and Hi milks, respectively (mean of three determinations7s.d.). The 0.009% sterols in the C milk were derived from contributions from the vegetable oils and milk fat. This translates to an estimated daily intake of 0.05, 1.17, and 1.60 g/day-very close to the desired values of 0.0 g/day (C), 1.2 g/day (Lo), and 1.6 g/day (Hi), and these latter values will be referred to throughout the remainder of the paper. Based on measurements from the Nestlé Quality Assurance Laboratories, the amount of cholesterol provided in the milk was 3.8 mg/100 g milk.
Proper solubilization of plant sterols and lack of plant sterol crystals 411 mm were determined by using a colorimetric quantification procedure combined with polarized light microscopy, differential interference microscopy (Zeiss Axioplan microscope; Zeiss, Jena, Germany), and particle sizing (Mastersizer 2000 static laser light scattering apparatus equipped with a Hydro 2000G large volume sampler; Malvern Instruments, Malvern, UK), as previously described (Pouteau et al, 2003) . Briefly, crystal quantification was performed using a filtration assay incorporating a 47 mm 11 mm nylon filter to trap sterol crystals. Crystals were then quantified with Sigma Infinity Cholesterol Reagent (SigmaAldrich), and absorbance was determined on an ELISA reader (Microplate Reader MRX, Dynatech Laboratories Inc., Embrach-Embraport, Switzerland). To verify that the sterols did not become crystallized during transport, milk samples were sent from Switzerland to Denmark, and then sent back to Switzerland at monthly intervals throughout the 3-month study for the above analyses. In milks that were sent from Denmark back to Switzerland, and analyzed 60 days postmanufacture (the mid-way point of the study), there were 0.1570.09 and 0.5670.05% (mean of 10 determinations7s.d.) of added plant sterols present as crystals 411 mm in the Lo and Hi milks, respectively. At the end of the study (120 days post-manufacture), there were no indications that the amount of sterols 411 mm had increased relative to 6-month-old milks, and there were no indications of sedimentation based on microscopic evaluation (micrographs not shown).
Study population, inclusion and exclusion criteria
The study subjects were recruited with local newspaper advertisements and soliciting among previous CCBR volunteers with known hypercholesterolemia. The participants were female or male volunteers, 45-65 y, with serum cholesterol between 5.6 and 8.4 mmol/l and serum triacylglycerol (TAG) less than 3.5 mmol/l. Of 138 patients screened, a medical doctor excluded patients due to: cholesterol 48.4 mmol/l (seven patients); cholesterol o5.6 mmol/l (fifteen); TAG 43.5 mmol/l (two); ingestion of drugs known to interfere with lipid profiles, that is, hormone replacement treatment, diuretics, and b-blockers (six); other abnormal laboratory values (three); lack of time/ vacation (six); and smoking 410 cigarettes/day, or having milk intolerance or dislike (seven). Other main exclusion criteria (not resulting in exclusions) were peanut allergies, diabetes, renal or liver disease, alcohol intake 43 U/day, and coffee intake 45 cups/day. In sum, 46 (33.3%) patients were excluded; 11 others were also excluded (41.3% total exclusions), despite fulfilling inclusion criterias, to achieve 81 predetermined patients for randomization. All participants gave written informed consent, and the study was approved by the local Danish Ethical Committee (Copenhagen County J. no. KA01135 g, approved October 31, 2001).
Scheduled visits
At the screening visit, a physical examination was performed, and a medical history was taken, including previous and present diseases and current medication. In addition, routine safety blood sample tests were performed to ensure normal health status, and serum total cholesterol and TAG were measured. When the subjects were found eligible for the study, the patients were randomized consecutively to one of the three different treatment sequences, and the study product was dispensed together with a diary for each study period.
After randomization, day 0 (d0), the subsequent visits were scheduled each second week. Visits were on d14 and 26 in the first period. The second period started at d27 with the next visits at d42 and 54. The third period started at d55 with the last visits at d70, 82, and 83, creating 11 visits altogether, including the screening and randomization visits.
Patients had their lipid profile performed at each visit, and at every second visit they were asked about their study product tolerance, specifically including any incidence of nausea, abdominal cramps, vomiting, diarrhea, and flatulence. At the end of each period (d27, 55, and 83), the excess study product was returned and counted as a measure of the patient compliance. A new study product was dispensed for each period, separately.
Dietary restrictions/daily diary
In the present work, we addressed the question of whether plant sterols in a milk matrix could lower cholesterol in Danes consuming their habitual, uncontrolled, Danish diet. However, restrictions were placed on the consumption, frequency, and intake quantity of foods that are very rich in cholesterol to assure that patients did not have a habitual cholesterol-rich diet far outside the norms of a typical Danish diet. Based on knowledge of the habitual Danish diet, a dietitian (B Decarli) designed a daily diary for subjects to complete and initialize, which set upper limits on certain foods. Food, cigarette, and beverage limits were as follows: r10 cigarettes/day; r3 glasses of wine or r2 beers or r1 unit of strong liquor/day; r5 cups/day coffee; r2 slices of cheese/day or r20 g/day; r2 portions of crustaceans and mollusks (shrimp, lobster, shellfish, etc)/week; and r3 portion seafood/week. Patients also recorded the consumption of: fish, eggs; meats with high-fat content such as sausage and offal; high-fat dairy foods such as eggs, creme fraiche, whipped cream, mayonnaise, and butter; and boiled Finnish style coffee. To minimize the possibility of gastrointestinal difficulties due to overconsumption of dairy products in general, other daily limits were: 250 ml of dairy product in the form of liquid milk, creamer, or yogurt; and two scoops of ice cream or its equivalent. The time of day when the study product was taken, excessive physical activity, illness, and any discomfort or new medications and vitamin intake were also recorded in the daily diary. Any subjects consuming quantities of cholesterol-rich foods in excess of that described above were considered on a case-bycase basis with respect to inclusion or exclusion in per protocol analysis. Compliance was evaluated at the end of the study. For each patient a day of full compliance was plotted as 1, whereas violation of the diet and lifestyle restrictions was plotted as 0. The mean value for each treatment period was calculated and compared.
Vital signs
Systolic and diastolic blood pressures (BP) were measured using an automatic manometer (UA-777, A&D Company, Limited, Japan) after the subjects had rested for at least 15 min. The patients' height and weight were measured at the first visit, and subsequently the weight was measured at the end of each treatment period. The body mass index (BMI) was calculated as: BMI¼weight/(height) 2 .
Laboratory measurements
All blood sample analyses were performed on venous blood taken from the participants in the morning after at least a 12 h overnight fast. The routine safety samples and serum lipids were spun for 10 min at 3000 r.p.m. and analysed with standardized methods on a weekly basis after À201C storage. Serum total cholesterol (intra-/interassay coefficient of variation (CV): 0.5%; 1.2%), serum high-density lipoprotein (HDL) (intra-/interassay CV: 0.7%; 2.6%) and LDL (intra-/ interassay CV: 0.5%; 2.3%), and serum TAG (intra-/interassay CV: 0.6%; 1.3%) were determined photometrically using the Hitachi 912 Clinical Chemistry Unit from Roche Diagnostics (Basel, Switzerland), following the recommended kit procedures.
Serum lipoprotein (a) (Lp(a)) (intra-/interassay CV: 2.2%; 9.2%) and serum apolipoprotein B (Apo B) (intra-/interassay CV: 1.1%; 3.1%) were determined using an immunoturbidimetric assay and the Hitachi 912 from Roche Diagnostics.
Serum samples for carotenoid and a-tocopherol analyses were stored at À801C and analyzed after study finalization by AS Vitas (Oslo, Norway) using HPLC. Intra-and interassay CVs were, respectively, 4.2-4.5 and 4.9-6.1% for carotenoids; and 3.8-4.4 and 4.6-4.8% for a-tocopherol.
Statistical analyses
Sample size was calculated assuming: a 5% clinically meaningful decrease in LDL (Hallikainen et al, 2000) , 11% conservatively (accounting for the s.d.); 5% type I error rate, 2.5% per dose (Bonferroni correction); and 90% power per dose. With a one sample t-test under these constraints, 63 subjects were required (calculated with Pass 6.0, NCSS, Kaysville, UT, USA). Assuming a 20% dropout rate, 79 subjects were needed, rounding to 81, since three equal groups were required.
The results are given as mean7s.d., and deemed statistically significant if Po0.05, unless stated otherwise. The main comparisons were made using the mean lipid value of the two measurements taken at the end of each 4-week treatment period; that is, corresponding with days 26 þ 27, 54 þ 55, and 82 þ 83. The different treatment periods were pooled creating the three intervention groups (C, Lo, Hi), and the percentage change was determined in relation to the end value from the pooled placebo group (C). Normal distribution was checked using the Kolmogorov-Smirnov test. In case a variable was not normally distributed, a logtransformation was performed; and if normal distribution was still not achieved, nonparametric analysis was employed (see table footnotes for details). Additionally, homogeneity of variances and test of sphericity was performed prior to further analyses.
For hypothesis testing, we used analysis of variance (ANOVA) for repeated measurements, General linear model (GLM). The gender and sequence of the three interventions were included in the linear models as between-subject factors in the first analysis, but excluded from the final analysis, if they did not show a significant effect on the efficacy parameters.
The treatment sequence had a significant effect on the percentage change in LDL (Po0.009, power¼0.8) and TAG (Po0.003), and the GLM was corrected for the specific treatment sequence in these two cases. Likewise, gender turned out as a significant cofactor for the change in mean total cholesterol (P¼0.002, power 0.89), mean LDL (P¼0.0004, power¼0.95), mean HDL, mean TAG, and mean Apo B. This was likely due to a significantly higher mean baseline lipid level among the male participants compared to females; therefore, these analyses were corrected for gender as well. Gender did not, however, influence the percentage change during study intervention in any of the lipid parameters.
The observed statistical power of the primary study objective showing the difference between the three interventions in mean and percentage change of LDL was 0.999 in both cases. Adjustment for multiple comparisons was made with the Bonferroni correction. All the statistical analyses were performed using SPSS for Windows 10.0 (SPSS Inc., Chicago, IL, USA).
Results
Study population at baseline and during the study The screen failure rate was 33.3% excluding 11 subjects, who fulfilled the inclusion criteria, but were excluded because the predetermined number of 81 subjects for randomization had already been reached. The three different treatment sequence groups were well matched at baseline regarding sex, age, BMI, BP, and baseline lipid profile ( No significant difference in diastolic and systolic BP or compliance to the diet recommendations during the study period was found; that is, the mean values for compliance violations were 0.8170.39 (C); 0.8070.40 (Lo); and 0.8370.38 (Hi), P¼1.00, also indicating that the average patient was fully compliant around 81% of the study days.
A total of 71 out of 81 patients (88%) completed the study; two patients were mistakenly given treatments in the wrong order (they received sequences C-Hi-Lo and Hi-Lo-C), and therefore despite causing no change in the overall results, were excluded from further analyses, resulting in 69 valid completers (85%).
Tolerability, adverse events, and discontinuations Tolerability criteria, adverse events, and serious adverse events were rigorously defined in the study protocol. There were no differences in the reported tolerability, nor frequency of adverse events, among the experimental groups. The tolerance parameters were as follows: abdominal cramps (2-C, 2-Lo, 3-Hi); flatulence (21-C, 18-Lo, 26-Hi); vomiting (0-C, 1-Lo, 0-Hi); diarrhea (2-C, 6-Lo, 2-Hi); and nausea (4-C, 4-Lo, 1-Hi). The totals were thus 29, 31, and 32 for C, Lo, and Hi groups, respectively. There were 71 reported adverse events during the treatment periods: 24 (C), 24 (Lo), and 23 (Hi). The most common adverse event was constipation. Other adverse events were breast tenderness (1-C, 2-Hi), itching, coughing, and bad breath.
The 10 study discontinuations were for the following reasons: hospitalization due to diverticulitis, the only serious adverse event (one patient); abdominal pain/constipation/ nausea (five), palpitations (one), and allergy (one), all classified as adverse events; and withdrawal due to vacations (two). The patient with diverticulitis was receiving placebo treatment at that time; the event was considered unrelated to the study product, since the patient had a history of diverticulosis coli before study participation.
LDL response
The mean LDL at study conclusion was 4.2170.77, 3.8770.68, and 3.7770.67 mmol/l in C, Lo, and Hi groups, respectively (Po0.0001 relative to C; Table 2 ). Thus, intake of 1.2 or 1.6 g/day (Lo or Hi group consumption) of unesterified, unhydrogenated, sterols, lowered serum LDL 7.13712.31% (Lo) and 9.59712.44% (Hi), respectively, compared to C (Po0.0001).
The sequence order significantly influenced LDL percentage change (Figure 1) . The mean percentage decrease in LDL adjusted for the placebo change (LDL/C) for each treatment sequence was: À0.15% (Lo) and À6.05% (Hi) for sequence 1 (C-Lo-Hi); À11.80% (Lo) and À9.40% (Hi) for sequence 2 (Lo-Hi-C); and À10.40% (Lo) and À13.81% (Hi) for sequence 3 (Hi-C-Lo), respectively. Sequences 2 and 3 did not significantly differ from one another (P¼1.0); however, Baseline characteristics of patients selected to receive milk products according to three sequences.
Free plant sterols in hypercholesterolemia AB Thomsen et al LDL response during sequence 1, starting with the placebo period, was significantly lower than during sequence 3 (P¼0.014), and borderline significantly different from sequence 2 (P¼0.051).
Responders were defined as participants with a decrease in LDL during both the Lo and Hi treatment periods. There were 50 responders, a total of 19 nonresponders, and 23.2 and 20.3% nonresponders in groups Lo and Hi, respectively. There was no significant difference between responders and nonresponders regarding baseline LDL (P¼0.35), baseline cholesterol (P¼0.71), or gender (P¼0.98). A tendency that nonresponders had a higher frequency in sequence 1, C-LoHi (P¼0.06) and were a little older than the responders (P¼0.08) was observed. The mean percent decrease in LDL/C adjusted for nonresponders was 12.1278.30% (Lo) and 14.3879.17% (Hi).
Other lipid parameters
There was a significant decrease in total cholesterol and Apo B in both intervention groups ( Table 2 ). The mean total cholesterol decreased from 7.0170.79 mmol/l at baseline to 6.6270.70 mmol/l (C), 6.2770.65 mmol/l (Lo) and 6.1370.67 mmol/l (Hi), respectively (Po0.0001). The percentage decrease in total cholesterol was À4.73% (Lo) and À7.05% (Hi) compared to C (Po0.0001) ( Table 2) .
Mean Apo B decreased from 136.2720.7 mg/dl at baseline to 132.1719.6 mg/dl (C), 126.2717.4 mg/dl (Lo), and 123.3718.1 mg/dl (Hi). The values were significantly different between C and the intervention groups (Po0.0001); and between Lo and Hi groups (P¼0.043). The mean percentage change of the intervention groups compared to C was À3.9378.00% (Lo) and À6.2878.69% (Hi); this was significant for both Lo and Hi vs C (Po0.0004), and Lo vs Hi (P¼0.038). Neither HDL nor TAG, or Lp(a) levels were significantly affected by sterol treatment.
Potential confounding factors
Including age and body weight as statistical cofactors did not affect overall results. Alcohol was examined as a confounder, since it was learned after the study that some participants consumed a higher amount of alcohol than recommended. However, the mean daily intake was still similar for the three groups: 1.0070.99, 1.0371.10 and 0.9571.08 U/day for C, Lo, and Hi groups, respectively. Therefore, bivariate correlation between the change in total cholesterol with units alcohol consumed during sterol treatment was not significant (P40.8).
Lipid levels were comparable in the three groups at baseline, and baseline cholesterol and LDL were not Free plant sterols in hypercholesterolemia AB Thomsen et al correlated with response to treatment. Therefore, baseline lipid levels were not included as covariates in the final ANOVA. Accordingly, despite significantly different mean values for baseline lipid parameters between men and women, there was no difference in treatment response between male and female subjects.
To evaluate a potential carry-over effect of the strongest dose, we tested for differences between 4 weeks Hi-and 2 weeks C values, when sequence order was Hi-C (n¼45, pooled sequence groups 2 and 3, Lo-Hi-C and Hi-C-Lo). We found a significant difference (Po0.0001), indicating that 2 weeks after ending the high-dose sterol treatment, serum cholesterol and LDL had significantly increased, confirming the short-term effect of sterols, and minimal interperiod carry-over risk.
Vitamins
The mean vitamin concentrations were within normal ranges at baseline, as well as after the three interventions (Table 3 ). There was no significant difference between the three groups at baseline.
A random test of 10 duplicates from our samples revealed, in all cases, an intra-assay precision lower or comparable to AS Vitas' CVs. The baseline values, intervention order, and gender did not influence the statistical outcome of the vitamin analyses and were therefore not included as covariates in the ANOVA.
There was a significant decrease in a-tocopherol after the Lo and Hi sterol doses (P¼0.0023 and 0.0002, respectively). a-Carotene and lutein were significantly lower only after consumption of the Hi dose (P¼0.016 and 0.033, respectively). Relative to C, percent changes after both interventions were significant for a-tocopherol (Po0.001), a-and bcarotene (P¼0.011 and 0.0003, respectively), and lycopene (P¼0.023; data not shown).
However, after standardizing vitamin concentrations to LDL during each intervention, there were no longer significant differences in mean or percentage changes of atocopherol (P¼0.06) or any of the carotenoids, relative to C (P¼0.25-0.90), except for lutein. The percentage change in lutein/LDL was borderline significant, P¼0.05 (data not shown).
Discussion
Reduction in LDL cholesterol and related parameters The daily intake of 1.2 g/day (Lo) or 1.6 g/day (Hi) of free unesterified, unhydrogenated sterols in a partly vegetable oil-filled low-fat milk reduced serum LDL significantly, by approximately 7 and 10%, respectively, compared to C.
Compared to baseline, LDL decrease was 2.7% (C), 10.2% (Lo), and 12.7% (Hi). The 2.7% decrease with placebo could be due to the consumption of control milk and/or to the dietary restrictions imposed, which could affect cholesterol and saturated fat intake (Yu et al, 1995) .
Our placebo-adjusted decrease of 7.13 and 9.59% with Lo and Hi doses is in accordance with results of other studies using a daily free sterol and stanol equivalent intake of 1.5-2.0 g/day (Hallikainen et al, 2000; Law, 2000) . Similar results have also been reported for 0.9-3.6 g/day of free sterols in dairy products, where placebo-adjusted LDL decreased 6.3-13.2% (Beer et al, 2001; Volpe et al, 2001 ). Enrichment of a low-fat yoghurt with 3 g/day of stanol equivalents, provided as stanol esters, reduced LDL 13.7% . Thus, the LDL-lowering effect of properly solubilized stanols or sterols, and their ester derivatives, seems to be similar in dairy products, as in spreads.
Presently, LDL was lowered even though our study subjects consumed their habitual diets, except for a few restrictions on highly cholesterol-rich food items. Based on previous studies (Hallikainen & Uusitupa, 1999; Maki et al, 2001; Volpe et al, 2001; Cleghorn et al, 2003; Maki et al, 2003) , LDL could also have been reduced, or reduced even further, relative to baseline, if subjects had consumed a very low-fat or cholesterol background diet. Consistent with decreased LDL, Apo B also decreased, more with the Hi than the Lo dose of sterols. Apo B is an index of LDL particle number, thus the Hi dose may have decreased numbers of LDL particles more than the Lo dose. Differences in numbers of small, dense, atherogenic LDL particles, and LDL oxidization (Schwab et al, 1998) are other important future parameters to assess.
We detected 23.2 and 20.3% nonresponders in Lo and Hi groups, respectively, and this is partially consistent with the previously observed variable ability of plant sterols to inhibit cholesterol absorption (Pouteau et al, 2003) .
Total cholesterol was reduced significantly with Lo and Hi sterol doses as well, but there were no significant changes in HDL, TAG, or Lp(a), as previously observed after treatment with other esterified (Miettinen et al, 1995; Hallikainen et al, 2000) or free (Volpe et al, 2001 ) plant sterol or stanol combinations.
Influence of the sequence of treatments Treatment sequence significantly influenced LDL (Figure 1 ). The first combination (C-Lo-Hi) resulted in the smallest LDL decline. The third combination (Hi-C-Lo) lowered LDL most effectively, despite a slightly-although not significantlyhigher baseline LDL. The second treatment sequence (LoHi-C) was also very effective. Theoretically, in the first sequence (C-Lo-Hi), Lo-and Hi-induced effects would be most directly attributed to plant sterols alone; however, in the real world people would often consume the plant sterol milk without changing any other dietary habits. Adherence to the dietary restrictions likely contributed to LDL lowering seen with C, Lo, and Hi during all sequences. Eating habits may also have been altered, since subjects are more conscious of their dietary intake in a controlled study. An experimental design with washout periods prior to each treatment, allowing LDL to return to baseline, would be another experimental strategy to determine dosage and sequence effects. Carry-over effects would also be minimized, but since plant sterols produce maximal effects in 2 weeks (see the section 'Potential confounding factors'; Hallikainen et al, 2002), this was not a major concern with the present experimental design. Dose-response, food matrix, and gender effects With the exception of Apo B, no assessed parameters showed a significant dose-response effect, thus, increasing the dose beyond 1.2 g/day, at least in the Danish population, cannot be recommended based on our data. Other data (Law, 2000; Christiansen et al, 2001) as well as recommendations from the American Heart Association (Lichtenstein & Deckelbaum, 2001 ), confirm the optimal dose of free phytosterols to be 1.5 g/day, that is, between our low and high dosage range.
Enrichment of food products with free plant sterols has proved to be very difficult, since sterols are insoluble in water and poorly soluble in dietary fats. The efficacy of the dose given depends on the physical form and structure in which the plant sterols are dissolved or dispensed (Ling & Jones, 1995; Christiansen et al, 2001) . Thus, to date most studies have incorporated plant sterol esters into spreads (Hendriks et al, 1999; Maki et al, 2001) . Ours is one of several recent studies to incorporate free sterols into a nonspread matrix, and the first to our knowledge, to examine nonesterified, nonhydrogenated plant sterols in a partly vegetable oil-filled low-fat milk matrix. Both nonesterified and esterified plant sterols have now been found to be efficacious when consumed in the following food matrices: oil-water emulsions (Gremaud et al, 2002) ; as aqueous vehicles with lecithin-sterol micelles ; yoghurt (Volpe et al, 2001; Mensink et al, 2002) ; milk (Beer et al, 2001) , chocolate (De Graaf et al, 2002) , cereal, snack bars, breads and beverages (Nestel et al, 2001; Maki et al, 2003) ; and beef/ hamburger (Matvienko et al, 2002) .
We developed a proprietary means to solubilize nonesterified, nonhydrogenated sterols in vegetable oil added to a milk fat matrix, with very few large crystals. The preliminary absorption experiments with a very similar study product as that employed presently showed large reductions in cholesterol absorption (Pouteau et al, 2003) , which is consistent with the currently observed reductions in LDL.
No difference in treatment response between male and female subjects was found, indicating that both genders will benefit from consuming this plant sterol-containing product. Noticeably, our study, unlike many other studies, included more women than men (Denke, 1995; Hallikainen & Uusitupa, 1999; Volpe et al, 2001 ).
Effects of plant sterols on fat-soluble vitamins
The overall safety of plant stanols and sterols has been previously reported Ostlund, 2002) ; but the influence of free and esterified sterols and stanols on fat-soluble vitamins and carotenoids has not been consistent (Hendriks et al, 1999; Hallikainen et al, 2000; Mensink et al, 2002; Ntanios et al, 2002) . Many previous studies have found that plant sterol and stanol esters decrease the carotenoids, especially the more lipophilic hydrocarbon carotenoids (aand b-carotene, lycopene) Mensink et al, 2002) .
We found a significant decrease in either the mean or the percentage change of a-tocopherol, a-and b-carotene, lycopene, and lutein. Similar decreases in these parameters have been reported for both sterol and stanol esters (Hallikainen et al, 2000; Plat et al, 2000; Maki et al, 2001) , and as in these studies, we also found that the mean concentration of antioxidants remained within the normal ranges both at baseline and postintervention.
Since the fat-soluble antioxidants are transported by lipoproteins, mainly VLDL and LDL, the change in lipoprotein fractions and in total cholesterol may explain the decrease in the mean concentration of antioxidants. Thus, a lipid-standardized ratio of the antioxidants with either total cholesterol or LDL is usually provided, but no consistency exists in the literature. Since the main effect of the study product was on LDL lowering, we chose to correct the vitamin and carotenoid values with LDL (Plat et al, 2000; Mensink et al, 2002) . After correcting for LDL changes, no significant difference in either the mean or percentage changes in any of the carotenoids or a-tocopherol was found. The only decrease that approached statistical significance was for LDL-normalised lutein. Other studies have also found that plant sterol and stanol esters (Hallikainen et al, 2000) and free sterols (Volpe et al, 2001 ) reduce fatsoluble vitamins, but that the decreases do not persist after LDL normalization. Whether there might be a difference in the effect of free sterols as compared to free stanols on lipophilic antioxidants, and whether the carrier food matrix may be important in this regard, are still unknown.
The critically important question of whether free sterols and stanols have less of an effect on lipophilic antioxidants than corresponding esterified products (theorized since free sterols will partition less into the oil layer during digestion) cannot be determined from our study, nor others in the literature. To address this question, it is necessary to compare free sterols and esters in the same study, prepared from the same starting material, and at the same free sterol molar equivalent dose. Recently, Raeini-Sarjaz et al (2002) compared esterified sterols and stanols, and found no differences in serum fat-soluble vitamins or carotenoid concentrations relative to control diet. However, the power to detect a statistically significant decrease would be limited since n¼15 persons.
It is recommended by the National Cholesterol Education Program (NCEP) (Grundy, 2001 ) to consume five servings of vegetables and fruits in the daily diet, and this has been shown to maintain plasma levels of antioxidants effectively, even when combined with sterol or stanol supplements (Noakes et al, 2002) . Additionally, in the latest NCEP guidelines, the importance of an aggressive therapeutic approach in the management of hypercholesterolemia is rigorously emphasized (Grundy, 2001) , and the necessary lifestyle changes and drug therapy should usually be considered life-long, emphasizing the substantial advantage of innovative dietary approaches.
Conclusion
The present study describes a substantial, reliable, and significant LDL cholesterol-lowering effect of a new low-fat milk product containing 1.2 and 1.6 g/day of free soybean oil-derived plant sterols, in a large, randomized, placebocontrolled trial. Subjects were hypercholesterolemic Danes, who consumed their habitual diets with some restrictions on high-fat foods. Based on previous studies, LDL cholesterol, relative to baseline, could also have been reduced, or reduced even further, if subjects had consumed a very low-fat or cholesterol background diet.
It was encouraging to find no LDL-normalized significant decreases in any of the carotenoids or a-tocopherols examined. These convincing results encourage further development of novel cholesterol-lowering, low-fat dairy products with nonesterified, nonhydrogenated plant sterols, expanding the food product alternatives for consumers, the functional food industry, and the global health service.
